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Abstract
Summary Osteoporosis is a well recognized complication
of ankylosing spondylitis (AS). This study indicates that
increased bone turnover, inflammation, and low vitamin D
levels are important in the pathophysiology of AS-related
osteoporosis, and that bone turnover markers (BTM) are
valuable markers to detect bone loss in AS.
Introduction The aim of this study was to elucidate the
pathophysiology of AS-related osteoporosis by investigat-
ing the relation between bone mineral density (BMD),
BTM, vitamin D, and clinical assessments of disease
activity and physical function, as well as to identify
parameters that are related to low BMD (osteopenia or
osteoporosis) in AS patients with active disease.
Methods One hundred twenty-eight consecutive Dutch AS
outpatients were included in this cross-sectional study. Bath
AS Disease Activity Index (BASDAI), erythrocyte sedimen-
tation rate (ESR), C-reactive protein, ASAS-endorsed disease
activity score (ASDAS), Bath AS Functional Index (BASFI),
bone formation markers procollagen type 1 N-terminal
peptide (PINP) and osteocalcin (OC), bone resorption
marker serum C-telopeptides of type I collagen (sCTX),
25-hydroxyvitamin D (25OHvitD), lumbar spine and hip
BMD, and vertebral fractures were assessed. Z-scores of
BTM were calculated using matched 10-year cohorts of a
Dutch reference group to correct for the normal influence
that age and gender have on bone turnover.
Results sCTX Z-score, OC Z-score, BASDAI, age, and
gender were independently related to low BMD. In
addition, PINP Z-score, ESR, 25OHvitD, age, and gender
were independently related to sCTX and/or OC Z-score.
Conclusions This study indicates that increased bone
turnover, inflammation, and low vitamin D levels are
important in the pathophysiology of AS-related osteoporo-
sis. Furthermore, sCTX and OC Z-scores seem to be
valuable markers to detect bone loss in AS patients in
daily clinical practice where BMD of the lumbar spine,
measured by DXA, may be overestimated due to osteopro-
liferation in patients with advanced AS.
Keywords Ankylosing Spondylitis.Bone mineral density.
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Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disease that primarily affects the axial skeleton. The disease
is characterized by new bone formation, which leads to the
formation of syndesmophytes and ankylosis of the spine and
sacroiliac joints. Osteoporosis is also a well-recognized
complication of AS and is already observed in early stages
of the disease. Early vertebral bone loss can be accompanied
by severe complications. Previous studies have shown that, in
contrasttonon-vertebralfractures,theriskofclinicalvertebral
fractures is increased in AS patients [1, 2] and that vertebral
fractures are frequently present in AS [3].
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osteoporosis is limited. Various studies have shown involve-
ment of inflammatory processes in the complex pathophysi-
ological mechanism of AS-related osteoporosis [4–9].
Furthermore, various other factors such as drug intake and
decreased mobility in relation to pain and stiffness may
contribute to the development of osteoporosis in AS patients
[10]. In addition, recent studies in AS have suggested that
alterations in vitamin D metabolism are associated with
inflammatory activity and bone mineral density (BMD) [7,
11–13]. Non-invasive assessment of biochemical bone
turnover markers (BTM) may provide more information
about the pathophysiology of osteoporosis [14–16]. So far,
conflicting data have been published about the relation
between BTM, BMD, and disease activity in AS [4, 9, 14,
15, 17–21].
BMD is usually monitored with dual-energy x-ray absorp-
tiometry(DXA) [22]. However, previous studies have shown
that the anterior-posterior lumbar spine BMD in AS can be
overestimated by the presence of syndesmophytes, ligament
calcifications, and fusion of facet joints [23–25]. Further-
more, measuring only hip BMD by DXA may not be
sufficient to identify all patients with AS-related osteoporosis
since bone loss may primarily occur in the spine [23].
Currently, quantitative computed tomography (QCT) is
considered to be the best technique to measure spinal BMD
in patients with advanced AS, since this technique can
measure only trabecular BMD [17, 24, 26]. However, QCT
is expensive and has a high radiation dose compared to DXA
[27].Therefore, an alternative method to monitor bone loss in
AS patients is desirable.
The aim of the present study was to elucidate the
pathophysiology of AS-related osteoporosis by investigating
the relation between BMD, BTM, vitamin D, and clinical
assessments of disease activity and physical function in a
cross-sectional cohort of AS patients with active disease, and
toidentifyparametersthatarerelatedtolowBMD(osteopenia
or osteoporosis) in these patients.
Methods
Patients
Between November 2004 and February 2009, 128 consecu-
tive Dutch AS outpatients from the Medical Center Leeuwar-
den (MCL, n=97) and the University Medical Center
Groningen (UMCG, n=31) were included in this cross-
sectional study. All patients were over 18 years of age,
fulfilled the modified New York criteria for AS [28], and
fulfilled the criteria for anti-tumor necrosis factor alpha (anti-
TNF-α) treatment according to the Assessments in Anky-
losing Spondylitis (ASAS) consensus statement [29]. Data
collected before start of anti-TNF-α treatment were used in
this cross-sectional study. Excluded were patients with the
concomitant presence of inflammatory bowel disease, chron-
ic renal or hepatic disease, diabetes mellitus, parathyroid or
thyroid disease, recent fractures, malnutrition, or drug intake
affecting bone metabolism (bisphosphonates, glucocorti-
coids, anticonvulsants, coumarin derivatives, or diuretics).
The study was approved by the local ethics committees of
the MCL and UMCG, and all patients provided written
informed consent to participate in this study.
Clinical and laboratory assessments
Disease activity was assessed using Bath Ankylosing Spon-
dylitis Disease Activity Index (BASDAI; on a scale of 0–10)
[30], erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), and ASAS-endorsed disease activity score
(ASDAS) calculated from BASDAI questions 2, 3, and 6,
patient's global assessment of disease activity, and CRP [31,
32]. Physical function was assessed using Bath Ankylosing
Spondylitis Functional Index (BASFI; on a scale of 0–10)
[33].
Bone turnover was studied by assessment of bone
formation markers procollagen type 1 N-terminal peptide
(PINP) and osteocalcin (OC), and bone resorption marker
serum C-telopeptides of type I collagen (sCTX) [14]. PINP
was measured by radioimmunoassay (RIA; Orion Diagnos-
tica, Espoo, Finland; inter-assay coefficient of variation (IE-
CV) 9.0%). OC was measured by immunoradiometric assay
(IRMA; BioSource Europe S.A; IE-CV 9.4%). sCTX was
measured by electrochemiluminescence immunoassay
(ECLIA; Elecsys 2010 Roche Mannheim, Germany; IE-CV
10.8%). Serum 25-hydroxyvitamin D (25OHvitD) levels
were measured by RIA (DiaSorin, Stillwater, MN, USA; IE-
CV 15%; UMCG and MCL until July 2008) or ECLIA
(Modular Analytics E170, Roche Mannheim, Germany; IE-
CV 7.1%; MCL since July 2008). 25OHvitD <50 nmol/L
was defined as a poor vitamin D status. Serum samples were
stored at −20°C until analysis.
Z-scores of BTM were used to correct for the normal
influence that age and gender have on bone turnover. Z-
scores, the number of standard deviations (SD) from the
normal mean for age and gender, were calculated using
matched10-yearcohortsofaDutchreferencegroup(150men
or 350 women), checked for serum 25OHvitD levels
>50 nmol/L as well as for lumbar spine and hip BMD T-
score >−2.5 after 50 years of age.
BMD measurement
BMDoflumbarspine(anterior-posteriorprojectionatL1–L4)
and hip (total proximal femur) were measured using DXA
(Hologic QDR Discovery (UMCG) or Hologic QDR Delphi
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Organization(WHO)classification,osteopeniawasdefinedas
a T-score between −1a n d−2.5 and osteoporosis as a T-score
≤−2.5 [34]. Patients were categorized by the lowest T-score
of the lumbar spine or hip. T-scores, the number of SD from
the normal mean obtained from young healthy adults, were
calculated using the NHANES reference database. DXA
measurements of lumbar spine and hip were available for
106 and 108 patients, respectively.
Vertebral assessment
Anterior, middle, and posterior heights of vertebrae T4 to L4
were measured on lateral radiographs by two independent
observers using a ruler. According to the Genant classifica-
tion, a vertebral fracture was defined based on reduction in
anterior, middle, and/or posterior height: grade 1, 20–25%
reduction; grade 2, 25–40% reduction; and grade 3, >40%
reduction [35]. In case of discrepancy between the two
observers, a third independent observer measured vertebral
height in order to confirm the presence or absence of a
vertebral fracture. Radiographs were available for 106
patients.
Statistical analysis
Statistical analysis was performed with SPSS 16.0 software
(SPSS, Chicago, IL, USA). Results were expressed as mean±
SD or median (range) for parametric and nonparametric data,
respectively. Pearson's and Spearman's correlation coeffi-
cients were used as appropriate to analyze the relationship
between BMD, BTM, vitamin D, and clinical measures of
disease activity and physical function. Predictor analysis for
low BMD, defined as lumbar spine or hip BMD T-score
≤−1, was performed using univariate logistic regression and
multivariate logistic regression with conditional stepwise
backward inclusion of variables that had a p value≤0.3 in
univariate analysis, together with variables that significantly
correlated with lumbar spine or hip BMD T-scores. The
probability of p for stepwise removal was 0.10. Predictor
analyses for sCTX and OC Z-scores were performed using
univariate linear regression and multivariate linear regression
with backward inclusion of variables that had a p value≤0.3
in univariate analysis, together with variables that signifi-
cantly correlated with sCTX or OC Z-scores. The probability
of F for removal was 0.10. p values≤0.05 were considered
statistically significant.
Results
Mean age of the 128 AS patients was 41.0 years (SD±
11.1), median disease duration was 14 years (range 1–53),
and 73% were male. Of the patients, 89% had a BASDAI
score ≥4, 74% had increased ESR levels, and 77% had
increased CRP levels (Table 1).
Correlations between biochemical and clinical assessments
Correlations between BMD, BTM, vitamin D, and clinical
assessments of disease activity and physical function were
calculated to obtain more knowledge about the pathophysiol-
ogy of AS-related osteoporosis (Table 2). There was a
significant positive correlation between lumbar spine and
hip BMD T-scores. Lumbar spine BMD T-score positively
correlated with BASDAI (p<0.05) and hip BMD T-score
negatively correlated with OC and sCTX Z-scores (p<0.05).
There were significant positive correlations between all
BTM Z-scores. PINP Z-score positively correlated with age
(p<0.05), and PINP and sCTX Z-scores positively correlated
with disease duration (p<0.05).Finally,ESR,CRP,ASDAS,
or BASFI were not significantly correlated with any of the
BMD T-scores or BTM Z-scores.
The difference between lumbar spine andhip BMD T-score
positively correlated with disease duration(ρ=0.340,p<0.05).
As shown in Fig. 1, patients with long disease duration never
had a lumbar spine BMD T-score that was much lower than
their hip BMD T-score, which indicates that osteoprolifera-
tion in the lumbar spine has resulted in an overestimation of
the lumbar spine BMD T-score in patients with advanced AS.
Vertebral fractures
Of the patients, 39% had at least 20% reduction in anterior,
middle, and/or posterior vertebral height, indicating vertebral
fracture. In total, 74 vertebral fractures were detected; 59
wedge fractures, 14 biconcave fractures, and one crush
fracture. No significant differences between patients with
and without vertebral fractures were found in age (mean
43.1 years±SD 11.1 vs. 39.9 years±11.0; p=0.149), disease
duration (median 15 years (range 1–47) vs. 12 years (1–53);
p=0.925), BMD T-scores (lumbar spine −0.70±1.33 vs.
−0.71±1.51; p=0.984, hip −0.47±1.03 vs. −0.59±1.10; p=
0.591), and BTM Z-scores (PINP 0.15 (−1.74–3.08) vs. 0.22
(−1.65–3.55); p=0.493), sCTX −0.21 (−2.28–5.90) vs.
−0.23 (−2.58–3.92); p=0.778), OC −0.31 (−2.86–1.50) vs.
−0.18 (−2.66–2.52); p=0.460, respectively).
Predictors of low BMD
Predictor analysis was performed to identify parameters that
are relatedtolowBMD.Intotal,57%ofpatientshadalumbar
spine or hip BMD T-score of −1 or less, indicating low BMD.
Male gender, lower BASDAI score, higher PINP Z-score,
higher OC Z-score, and higher sCTX Z-score were signifi-
cantly associated with low BMD in univariate regression
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low BMD, variables that significantly differed between men
and women were included in multivariate analysis: age, ESR,
OC Z-score, sCTX Z-score, and 25OHvitD. Multivariate
regression analysis showed that older age (odds ratio (OR):
1.066, 95% confidence interval (CI): 1.008–1.129), lower
BASDAI score (OR: 0.648, 0.445–0.923), higher ESR (OR:
1.025, 0.994–1.057), and higher sCTX Z-score (OR: 2.563,
1.370–4.794) were independently related to low BMD
(Table 3). OC Z-score was not included in multivariate
analysis, probably due to the strong correlation between
sCTX Z-score and OC Z-score (ρ=0.601, p=0.000).
However, higher OC Z-score was also independently related
to low BMD in the presence of age, BASDAI, and ESR
(OR: 2.255, 1.238–4.107), indicating that both sCTX Z-score
and OC Z-score are important. The Nagelkerke R
2 of the
multivariate models including sCTX Z-score and OC Z-score
were 0.381 and 0.338, respectively.
Predictors of sCTX and OC Z-scores
Since sCTX and OC Z-scores seem to be valuable markers to
detect bone loss, predictor analyses for these markers were
performed toget more information about the pathophysiology
of AS-related osteoporosis. Gender, PINP Z-score, OC Z-
score,and25OHvitDweresignificantlyassociatedwithsCTX
Z-score in univariate regression analysis. Since gender was
significantly associated with sCTX Z-score, the previous
mentioned variables that significantly differed between men
and women were included in multivariate analysis. Multivar-
iate regression analysis showed that ESR (OR: 0.012, 0.000–
0.025), PINP Z-score (OR: 0.292, 0.022–0.563), OC Z-score
(OR: 0.505, 0.243–0.768), and 25OHvitD (OR: −0.009,
−0.018–0.000) were independently related to sCTX Z-score
(Table 4). The R
2 of this multivariate model was 0.424.
Gender,PINPZ-score,andsCTXZ-scoreweresignificantly
associated with OC Z-score in univariate regression analysis.
Table 1 Characteristics of the AS study population (n=128)
Age (years) 41.0±11.1
Gender (male) (n, %) 93 (73)
Disease duration (years) 14 (1–53)
HLA-B27+ (n, %) 102 (84)
NSAID use (n, %) 100 (78)
DMARD use (n, %) 18 (14)
BASDAI (range 0–10) 6.0±1.6 BASDAI≥4( n, %) 116 (89)
ESR (mm/h) 20 (2–90) Increased ESR (n, %) 95 (74)
CRP (mg/L) 14 (2–92) Increased CRP (n, %) 99 (77)
ASDAS 3.7±0.8
BASFI (range 0–10) 5.6±2.0
LS BMD T-score −0.68±1.41 Osteopenia LS (n, %) 41 (39)
Osteoporosis LS (n, %) 9 (9)
Hip BMD T-score −0.52±1.06 Osteopenia hip (n, %) 42 (39)
Osteoporosis hip (n, %) 2 (2)
VF (n, %) 41 (39) VF grade 1 (n, %) 27 (25)
VF grade 2 (n, %) 14 (13)
VF grade 3 (n, %) 0 (0)
PINP (μg/L) 42.7 (16.0–101.5)
PINP Z-score 0.14 (−1.74–3.55)
sCTX (pg/ml) 200.3 (13.4–780.9)
sCTX Z-score −0.36 (−2.58–5.90)
OC (μg/L) 12.7 (0.1–24.9)
OC Z-score −0.28 (−2.86–2.52)
25OHvitD (nmol/L) 61.4 (13.8–186) Poor vitamin D status (n, %) 30 (26)
Values are mean±SD or median (range) unless otherwise indicated
AS Ankylosing Spondylitis, HLA-B27+ human leukocyte antigen B27 positive, NSAID non-steroidal anti-inflammatory drug, DMARD disease-
modifying antirheumatic drug, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ESR erythrocyte sedimentation rate, CRP C-reactive
protein, ASDAS ASAS-endorsed disease activity score, BASFI Bath Ankylosing Spondylitis Functional Index, LS lumbar spine, BMD bone
mineral density, VF vertebral fracture, PINP procollagen type 1 N-terminal peptide, sCTX serum C-telopeptides of type I collagen, OC
osteocalcin, 25OHvitD 25-hydroxyvitamin D
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previous mentioned variables that significantly differed be-
tween men and women were included in multivariate analysis.
Multivariate regression analysis showed that age (OR: −0.018,
−0.034–−0.001), gender (OR: −0.607, −0.999 –−0.214), PINP
Z-score (OR: 0.464, 0.282–0.646), and sCTX Z-score (OR:
0.243, 0.110–0.377) were independently related to OC Z-score
(Table 5). The R
2 of this multivariate model was 0.509.
Discussion
The present cross-sectional study in AS patients with active
diseaseshowedthatsCTXandOCZ-scoresareindependently
related to low BMD, which indicates that sCTX and OC Z-
scores are valuable markers to detect bone loss in AS. An
accurateandeasilyaccessiblemarkerofbonelossisneededin
patientswithadvancedAS,sincetheanterior-posteriorlumbar
spine BMD measured by DXA can be overestimated by the
presence of syndesmophytes, ligament calcifications, and
fusion of facet joints in these patients [23–25]. Our finding
that the difference between lumbar spine and hip BMD
positively correlated with disease duration indicates that this
overestimation also occurred in this study. Furthermore, our
high prevalence of vertebral fractures and of low BMD
(osteopenia or osteoporosis) underlines the importance of
monitoring bone loss in AS.
In order to obtain more knowledge about the pathophys-
iologyofAS-relatedosteoporosis,weinvestigatedtherelation
between BMD, BTM, vitamin D, and clinical assessments.
Our results demonstrate that increased bone turnover plays a
significant role in the development of osteoporosis in AS
Table 2 Correlations between clinical and biochemical assessments in AS patients with active disease (n=128)
Age Disease
duration



















ESR (mm/h) NS NS NS –















a NS NS NS NS NS –
sCTX Z-score NS 0.200
a NS NS NS NS NS 0.443
a –






a NS NS NS NS NS NS NS –
Hip BMD
T-score






NS NS NS NS NS NS NS NS NS NS NS NS
aStatistically significant correlation (p<0.05)
See Table 1 for definitions
Fig. 1 The difference between lumbar spine and hip BMD T-score
positively correlated with disease duration (ρ=0.340, p<0.05).
Patients with long disease duration never had a lumbar spine BMD
T-score that was much lower than their hip BMD T-score, which
indicates that osteoproliferation in the lumbar spine has resulted in an
overestimation of the lumbar spine BMD T-score in patients with
advanced AS
Osteoporos Int (2011) 22:1431–1439 1435Table 3 Results of univariate and multivariate logistic regression analysis for low BMD
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Age (years)
a 1.017 (0.981–1.055) 0.353 1.066 (1.008–1.129) 0.026
Gender
b 4.368 (1.791–10.652) 0.001 –
e
Disease duration (years)
a 1.012 (0.974–1.052) 0.539 –
e
BASDAI (range 0–10)
c 0.728 (0.554–0.957) 0.023 0.648 (0.455–0.923) 0.016
ESR (mm/h)
c 1.012 (0.980–1.034) 0.287 1.025 (0.994–1.057) 0.112
CRP (mg/L)
c 1.018 (0.994–1.042) 0.143 –
e
ASDAS
c 0.769 (0.461–1.283) 0.315 –
f
BASFI (range 0–10)
c 0.959 (0.790–1.165) 0.674 –
f
PINP Z-score
c 1.602 (1.043–2.461) 0.031 –
e
sCTX Z-score
c 1.878 (1.262–2.794) 0.002 2.563 (1.370–4.794) 0.003
OC Z-score
c 1.766 (1.135–2.749) 0.012 –
e
25OHvitD (nmol/L)
c 0.998 (0.983–1.013) 0.787 –
e
VF
d 0.902 (0.385–2.109) 0.811 –
f
See Table 1 for definitions
OR refers to the risk of low BMD (lumbar spine or hip BMD T-score≤−1)
aPer year
bIf gender is male (versus female)
cPer 1 grade or 1 point
dIf vertebral fracture is present (versus absent)
eThe variable was not selected during multivariate regression analysis
fThe variable was not tested in multivariate regression analysis because of a p value>0.3 in univariate regression analysis, no significant correlation with
lumbar spine or hip BMD T-scores, and no significant difference between men and women
Table 4 Results of univariate and multivariate linear regression analysis for sCTX Z-score
Univariate analysis Multivariate analysis
B (95% CI) p value B (95% CI) p value
Age (years)
a 0.018 (−0.004–0.041) 0.112 –
d
Gender
b −0.680 (−1.211–−0.148) 0.013 –
d
Disease duration (years)
a 0.018 (−0.005–0.041) 0.114 –
d
BASDAI (range 0-10)
c −0.060 (−0.213–0.092) 0.436 –
e
ESR(mm/h)
c 0.011 (−0.002–0.025) 0.102 0.012 (0.000−0.025) 0.069
CRP(mg/L)
c 0.007 (−0.007–0.021) 0.303 –
d
ASDAS
c 0.156 (−0.174–0.486) 0.351 –
e
BASFI (range 0–10)
c 0.004 (−0.124–0.132) 0.953 –
e
PINP Z-score
c 0.581 (0.384–0.777) 0.000 0.292 (0.022–0.563) 0.035
OC Z-score
c 0.774 (0.577–0.971) 0.000 0.505 (0.243–0.768) 0.000
25OHvitD (nmol/L)
c −0.011 (−0.020–−0.002) 0.020 −0.009 (–0.018–0.000) 0.041
See Table 1 for definitions
B refers to the influence on sCTX Z-score
aPer year
bIf gender is male (versus female)
cPer 1 grade or 1 point
dThe variable was not selected during multivariate regression analysis
eThe variable was not tested in multivariate regression analysis because of a p value>0.3 in univariate regression analysis, no significant correlation with
sCTX Z-score, and no significant difference between men and women
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between age or disease duration and PINP Z-score, a marker
of bone formation, as well as between disease duration and
sCTX Z-score, a marker of bone resorption. Since the use of
Z-scores corrects for the normal influence that age and gender
haveonboneturnover, these correlationsdemonstratethatAS
is characterized by both increased bone formation and
increased bone resorption. Second, significant negative
correlations were found between sCTX or OC Z-scores and
hip BMD T-score, and a higher sCTX or OC Z-score was
independently related to low BMD, which indicates that high
bone turnover is associated with bone loss in AS. This finding
is in agreement with the previous studies [4, 14, 15].
The results of this study also demonstrate involvement of
inflammatory processes in the complex pathophysiological
mechanism of AS-related osteoporosis. A higher ESR was
independently related to low BMD. Furthermore, ESR had
independent influence on sCTX Z-score. The importance of
inflammatory processes was also shown in previous studies
[4–9].
Finally, our finding that 25OHvitD level had an indepen-
dent significant inverse influence on sCTX Z-score suggests
that low vitamin D levels play a role in the development of
AS-related osteoporosis. The importance of vitamin D was
also suggested in previous studies [7, 11–13, 36]. Amento et
al. reported that vitamin D is an endogenous modulator of
the immune response, which may slow down the inflamma-
tory process by suppressing active T cells and cell
proliferation [36]. Lange et al. found negative correlations
between serum levels of vitamin D and markers of disease
activity or inflammation in AS patients. They also showed
that AS patients with osteoporosis had significantly lower
vitamin D levels compared to AS patients with normal BMD
[7, 11]. Finally, Obermayer et al. suggested a close
association of BMD, bone metabolism, and inflammatory
activity with Fok1 polymorphisms of the vitamin D receptor
gene in male AS patients [13].
Unexpectedly, a lower BASDAI score was independently
related to low BMD in this study. A possible explanation for
this finding may be that complaints related to new bone
formation influence the BASDAI, a subjective measure of
disease activity, in AS patients with active disease. The
significant positive correlation between BASDAI and lumbar
spine BMD T-score found in this study seems to confirm this
suggestion. Another explanation may be thatBMD, measured
by DXA, reflects the influence of the disease on bone over
time, while BASDAI reflects the current status of disease
activity.
There are some strengths and limitations to this study. The
main limitation is that the study is cross-sectional and that
only AS patients with active disease were included. Further
studies with longer follow-up are needed to confirm the
usefulness of sCTX and OC Z-scores in monitoring bone loss
in AS patients, as well as the importance of increased bone
Table 5 Results of univariate and multivariate linear regression analysis for OC Z-score
Univariate analysis Multivariate analysis
B (95% CI) p value B (95% CI) p value
Age (years)
a 0.008 (−0.011–0.027) 0.409 −0.018 (−0.034–−0.001) 0.036
Gender
b −0.687 (−1.129–−0.244) 0.003 −0.607 (−0.999–−0.214) 0.003
Disease duration (years)
a 0.007 (−0.012–0.026) 0.460 –
e
BASDAI (range 0–10)
c −0.029 (−0.155–0.098) 0.655 –
e
ESR (mm/h)
c 0.006 (−0.005–0.018) 0.284 –
d
CRP (mg/L)
c 0.009 (−0.003–0.022) 0.130 –
d
ASDAS
c 0.052 (−0.222–0.326) 0.708 –
e
BASFI (range 0–10)
c 0.035 (−0.071–0.141) 0.651 –
e
PINP Z-score
c 0.605 (0.453–0.756) 0.000 0.464 (0.282–0.646) 0.000
sCTX Z-score
c 0.464 (0.346–0.582) 0.000 0.243 (0.110–0.377) 0.000
25OHvitD (nmol/L)
c −0.007 (−0.016–0.001) 0.076
See Table 1 for definitions
B refers to the influence on OC Z-score
aPer year
bIf gender is male (versus female)
cPer 1 grade or 1 point
dThe variable was not selected during multivariate regression analysis
eThe variable was not tested in multivariate regression analysis because of a p value>0.3 in univariate regression analysis, no significant correlation with
OC Z-score, and no significant difference between men and women
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developmentofAS-relatedosteoporosis.Anotherlimitationis
that body mass index (BMI) was not assessed in this study.
Therefore, it was not possible to correct for low BMI in
multivariate analysis. Finally, it was not clear if the vertebral
fractures occurred recently or if they were already present for
many years. Therefore, analyses investigating the relation
betweenBTM and vertebral fractures weredifficult. Themain
strengthisthatZ-scoresofBTMwerecalculatedtocorrect for
the influence that age and gender have on bone turnover in
healthy persons. In this way, male and female patients of
different age groups could be analyzed together.
In conclusion, this cross-sectional study in AS patients
with active disease indicates that increased bone turn-
over, inflammation, and low vitamin D levels are
important in the pathophysiology of AS-related osteopo-
rosis. Furthermore, sCTX and OC Z-scores seem to be
valuable markers to detect bone loss in AS. Combining
biochemical BTM and BMD measurements may be
useful to identify AS patients with osteoporosis in daily
clinical practice where lumbar spine BMD, measured by
DXA, may be overestimated due to osteoproliferation in
patients with advanced AS.
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